Retrospective Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 6, 2021; 9(28): 8349-8357
Published online Oct 6, 2021. doi: 10.12998/wjcc.v9.i28.8349
Clinical observation of Kuntai capsule combined with Fenmotong in treatment of decline of ovarian reserve function
Xin-Miao Lin, Miao Chen, Qiao-Ling Wang, Xiao-Min Ye, Hao-Fan Chen
Xin-Miao Lin, Miao Chen, Qiao-Ling Wang, Xiao-Min Ye, Hao-Fan Chen, Department of Reproductive Health and Infertility, Zhanjiang Central People’s Hospital, Zhanjiang 524037, Guangdong Province, China
Author contributions: Lin XM designed the experiment; Chen M drafted the work, Chen HF, Wang QL and Ye XM collected the data; Lin XM analysed and interpreted data; Chen M wrote the article. Lin XM and Chen M contributed equally.
Institutional review board statement: This manuscript was approved by the Medical Ethics Committee of Zhanjiang Central Hospital.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: The authors declared that there is no conflict of interest between them.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hao-Fan Chen, PhD, Chief Doctor, Department of Reproductive Health and Infertility, Zhanjiang Central People’s Hospital, No. 236 Yuanzhu Road, Chikan District, Zhanjiang 524037, Guangdong Province, China. tony_chen8928@163.com
Received: May 27, 2021
Peer-review started: May 27, 2021
First decision: June 24, 2021
Revised: July 4, 2021
Accepted: August 5, 2021
Article in press: August 5, 2021
Published online: October 6, 2021
Processing time: 124 Days and 0.4 Hours
Abstract
BACKGROUND

Decreased ovarian reserve function is an ovarian hypofunction disease that occurs in women before 40 years of age, leading to a decline in fertility and perimenopausal symptoms, such as irregular menstruation, amenorrhea, infertility, decreased libido, and autonomic nervous dysfunction. Fenmatong (FMT) is a compound mixture of estradiol tablets and estradiol didroxyprogesterone tablets, which can improve ovarian reserve function by supplementation of exogenous estrogen. However, this treatment has also been shown to cause breast pain, gastrointestinal discomfort, irregular vaginal bleeding, and changes in sexual desire. In severe cases, FMT can promote the development of breast cancer, endometrial cancer, and venous embolic disease.

AIM

To observe the effects of Kuntai capsules and FMT on endocrine indexes and uterine artery blood circulation in patients with decreased ovarian reserve function.

METHODS

Patients (130) with decreased ovarian reserve function, who were treated in our hospital from May 2018 to May 2020, were divided into two groups: The FMT group, in which patients were treated with FMT, and the observation group, in which patients were treated with Kuntai capsules. Chinese medicine symptom scores, uterine artery blood flow parameters, ovarian ultrasound test indexes, pictorial blood loss assessment chart (PBAC) scores, and hormone levels were recorded, and total effective rates were calculated for both groups.

RESULTS

The total effective rate in the observation group was higher than that in the FMT group (P < 0.05).After treatment, primary symptoms, including low menstrual volume, delayed menstruation, red color and thick consistency of menses, dizziness, palpitation, weakness at the waist and knee, insomnia and excessive dreaming, irritability, and dryness and astringency of the pudendal canal in the observation group decreased, and scores for primary and secondary symptoms in the observation group were significantly lower than those in the FMT group (P < 0.05).The systolic peak flow rate (PSV), end-diastolic flow rate (EDV), ovarian diameter, sinus follicle count, and resistance index (RI) of the uterine arteries in the observation group and FMT group increased after treatment. Notably, the PSV, EDV, ovarian diameter, and antral follicle count in the observation group were higher than those in the FMT group, whereas the RI in the observation group was lower than that in the FMT group (P < 0.05).The PBAC scores in the observation and FMT groups increased after treatment, with that in the observation group becoming significantly higher than that in the FMT group (P < 0.05). After treatment, estradiol (E2) and anti-Mullerian hormone (AMH) levels increased, whereas follicle-stimulating hormone (FSH) levels decreased in the observation group and FMT group; E2 and AMH levels became significantly higher and FSH levels became significantly lower in the observation group than in the FMT group (P < 0.05).

CONCLUSION

Compared with FMT, Kuntai capsules promoted uterine artery blood circulation, improved menstruation, relieved symptoms, regulated endocrine function, and improved curative effects.

Keywords: Kuntai capsule; Fenmatong; Ovarian reserve function decline; Endocrine index; Blood circulation

Core Tip: This paper verified that Kuntai capsule combined with Fenmatong in the treatment of decreased ovarian reserve function can promote uterine artery blood circulation, improve menstruation, alleviate symptoms, regulate endocrine and improve the curative effect.